Accurate and high-throughput measurement of neutralization antibody titers in serum samples from SARS-CoV-2 infected patients

Supported by GenScript USA Inc.

Overview

With the oncoming SARS-CoV-2 vaccination programs soon to be initiated globally, many questions have arisen concerning the efficacy and duration of protection. The focus on a subset of immune response antibodies that block and effectively neutralize the interaction between the virus and host cells has become a key measure of vaccine efficacy. However, their measurement is challenging with the pre-existing live cell neutralization tests that are considered gold standard. A newly available assay termed cPass Surrogate Virus Neutralization Test (cPassTM sVNT) permits the qualitative and quantitative evaluation of neutralizing antibodies in a simple, cost-effective, and high-throughput test. Samples from SARS-CoV-2 recovered individuals exhibited differences up to 400-fold in neutralizing antibody titers demonstrating the practical application of cPass sVNT to assess: 1) strength of immune response between both infected and vaccinated individuals; 2) level of protection against re-infection, and 3) duration of protection post-infection/vaccination.

Presenter

Sean Taylor
Field Application Scientist Manager
GenScript USA Inc.